Pro-Dex, Inc. (PDEX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pro-Dex, Inc. (PDEX) trades at $61.33 with AI Score 82/100 (Grade A+). Pro-Dex, Inc. is a leading manufacturer of powered surgical instruments, primarily serving the orthopedic, thoracic, and craniomaxillofacial markets. Market cap: $195.81M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for PDEX: PDEX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PDEX against Healthcare peers across nine fundamental dimensions and assigns a relatively strong fundamental profile based on the underlying data.
PDEX: 2/4 perspectives are bullish. Dominant signal: Moon AI bullish.
How is this calculated? →Pro-Dex, Inc. (PDEX) Healthcare & Pipeline Overview
Pro-Dex, Inc. specializes in designing and manufacturing powered surgical instruments for medical device OEMs, focusing on orthopedic, thoracic, and craniomaxillofacial applications, with a strong commitment to quality and regulatory compliance.
What Is the Investment Thesis for PDEX?
Pro-Dex, Inc. presents a compelling investment thesis driven by its strong financial metrics and strategic positioning within the medical instruments sector. With a market capitalization of $195.81M and a P/E ratio of 14.7, the company demonstrates solid profitability, evidenced by a profit margin of 16.1%. Growth catalysts include the increasing demand for powered surgical instruments in orthopedic and thoracic surgeries, which are projected to expand as the global healthcare market grows. Additionally, Pro-Dex’s consulting services enhance customer loyalty and open new revenue streams. The company’s focus on regulatory compliance and quality assurance further strengthens its competitive edge. However, potential risks include market fluctuations and regulatory challenges that could impact operational efficiency. Overall, Pro-Dex's robust product offerings and commitment to innovation position it well for sustained growth in the evolving healthcare landscape.
Based on FMP financials and quantitative analysis
PDEX Key Highlights
- Market capitalization of $195.81M reflects a solid position in the medical instruments sector.
- P/E ratio of 14.7 indicates attractive valuation relative to earnings.
- Profit margin of 16.1% showcases operational efficiency and profitability.
- Gross margin of 27.8% exceeds industry averages, highlighting effective cost management.
- Beta of -0.11 suggests lower volatility compared to the broader market.
Who Are PDEX's Competitors?
PDEX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SYK Stryker Corporation | $326.54 | +4.20% | $125.18B | 79 |
| ZBH Zimmer Biomet Holdings, Inc. | $87.47 | +3.92% | $16.92B | 79 |
| MDT Medtronic plc | $83.19 | +5.04% | $106.49B | 77 |
| BSX Boston Scientific Corporation | $45.14 | +4.83% | $67.09B | 82 |
| JNJ Johnson & Johnson | $263.04 | +3.57% | $633.20B | 90 |
| NYXH Nyxoah S.A. | $1.72 | -3.37% | $68.12M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $26.98 | +2.66% | $1.57B | 67 |
| ZTEK Zentek Ltd. | $0.45 | -3.63% | $48.50M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PDEX's Key Strengths?
- Established brand with a strong reputation in the medical instruments sector.
- Diverse product offerings that cater to multiple surgical markets.
- Strong profit margins indicating effective cost management.
- Expertise in regulatory compliance enhances market credibility.
What Are PDEX's Weaknesses?
- Limited market presence compared to larger competitors.
- Dependence on a narrow range of products for revenue generation.
- No dividend yield may deter income-focused investors.
- Relatively small workforce may limit production capacity.
What Could Drive PDEX Stock Higher?
- Expansion of product lines to include more advanced surgical instruments tailored for minimally invasive procedures.
- Continuous improvement in operational efficiency leading to sustained profit margins above industry averages.
- Strategic partnerships with key OEMs to co-develop innovative surgical solutions.
- Increasing demand for consulting services as healthcare regulations become more complex.
- Geographic expansion efforts targeting emerging markets with growing healthcare infrastructure.
What Are the Key Risks for PDEX?
- Regulatory changes that could affect product approval processes and timelines.
- Intense competition from larger medical device manufacturers impacting market share.
- Economic fluctuations that may reduce healthcare spending and impact sales.
- Dependence on a limited range of products may expose the company to market volatility.
What Are the Growth Opportunities for PDEX?
- Growth opportunity 1: The global orthopedic surgical instruments market is projected to reach $45 billion by 2028, growing at a CAGR of 6.5%. Pro-Dex can capitalize on this growth by expanding its product offerings and enhancing its marketing strategies to reach more OEMs in this sector.
- Growth opportunity 2: The increasing trend towards minimally invasive surgeries is driving demand for advanced surgical instruments. Pro-Dex's focus on developing innovative, multi-functional surgical drivers and shavers positions it to capture a larger market share in this growing segment, expected to grow at a CAGR of 7% over the next five years.
- Growth opportunity 3: Expanding its consulting services can open new revenue streams. With healthcare regulations becoming more complex, Pro-Dex can leverage its expertise to offer comprehensive consulting solutions, targeting a market estimated at $10 billion by 2027.
- Growth opportunity 4: Strategic partnerships with leading medical device manufacturers can enhance Pro-Dex's market presence. Collaborations can lead to co-development of new technologies, tapping into the growing demand for innovative surgical solutions, which is projected to increase by 5% annually.
- Growth opportunity 5: Geographic expansion into emerging markets presents significant potential. As healthcare infrastructure improves in regions like Asia-Pacific and Latin America, Pro-Dex can establish a foothold, targeting a market anticipated to grow at a CAGR of 8% through 2030.
What Opportunities Does PDEX Have?
- Growing demand for minimally invasive surgical instruments.
- Expansion into emerging markets with increasing healthcare needs.
- Potential for strategic partnerships with larger medical device firms.
- Increasing complexity of healthcare regulations driving demand for consulting services.
What Threats Does PDEX Face?
- Intense competition from larger, established medical device companies.
- Regulatory changes that could impact product approval timelines.
- Economic downturns affecting healthcare spending.
- Technological advancements by competitors that could outpace Pro-Dex's offerings.
What Are PDEX's Competitive Advantages?
- Strong focus on regulatory compliance and quality assurance.
- Established reputation in the orthopedic and surgical instruments market.
- Diverse product offerings that cater to multiple surgical specialties.
- Expertise in engineering and consulting services enhances customer loyalty.
- Long-standing relationships with OEMs provide competitive advantages.
What Does PDEX Do?
Founded in 1978, Pro-Dex, Inc. has established itself as a pivotal player in the healthcare sector, specifically within the medical instruments and supplies industry. Headquartered in Irvine, California, the company designs, develops, and manufactures powered surgical instruments tailored for original equipment manufacturers (OEMs) in the medical device field. Pro-Dex’s product portfolio includes autoclavable, battery-powered, and electric multi-function surgical drivers and shavers, which are predominantly utilized in orthopedic, thoracic, and craniomaxillofacial surgeries. Over the years, the company has evolved to not only focus on surgical instruments but also to provide engineering, quality, and regulatory consulting services, thereby enhancing its value proposition to clients. Additionally, Pro-Dex manufactures and sells rotary air motors to various industries, diversifying its revenue streams. With a workforce of 146 employees, the company emphasizes innovation and quality, maintaining a profit margin of 16.1% and a gross margin of 27.8%. Pro-Dex's commitment to excellence and compliance with regulatory standards positions it favorably within a competitive landscape, catering to a global market of medical device manufacturers.
What Products and Services Does PDEX Offer?
- Design and manufacture powered surgical instruments for medical device OEMs.
- Offer a range of autoclavable, battery-powered, and electric surgical drivers and shavers.
- Provide engineering, quality, and regulatory consulting services to enhance compliance.
- Manufacture and sell rotary air motors for various industrial applications.
- Focus on orthopedic, thoracic, and craniomaxillofacial surgical markets.
- Commit to high standards of quality and regulatory compliance in all products.
How Does PDEX Make Money?
- Generate revenue through the sale of powered surgical instruments to OEMs.
- Offer consulting services that provide additional revenue streams.
- Manufacture rotary air motors for diverse industrial applications.
- Focus on high-margin products to enhance profitability.
- Leverage strong relationships with OEMs to ensure repeat business.
What Industry Does PDEX Operate In?
The medical instruments and supplies industry is experiencing significant growth, driven by advancements in surgical technology and an increasing number of surgical procedures globally. The orthopedic market, in particular, is expected to expand as the aging population requires more surgical interventions. Pro-Dex, Inc. is well-positioned within this landscape, focusing on powered surgical instruments that meet the evolving needs of healthcare providers. The competitive landscape includes various players, but Pro-Dex differentiates itself through its commitment to quality and regulatory expertise, which are critical in this highly regulated industry.
Who Are PDEX's Key Customers?
- Original equipment manufacturers (OEMs) in the medical device sector.
- Healthcare providers requiring advanced surgical instruments.
- Industries needing rotary air motors for various applications.
- Regulatory bodies seeking compliance consulting services.
- Surgical teams in hospitals and clinics using powered instruments.
FY2026 estForward Outlook
Wall Street analysts project Pro-Dex, Inc. revenue of about $76.4M for fiscal 2026, with EPS near $3.94.
PDEX Valuation & Market Position
With a $195.81M market cap, Pro-Dex, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PDEX's quantitative score of 82/100 is roughly in line with the peer average of 81/100.
ROE 29%Key Financial Metrics
Return on equity for Pro-Dex, Inc. stands at 29.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.0%, showing how much profit it generates from its asset base. PDEX trades at a trailing price-to-earnings ratio of 14.69, below the Healthcare sector average of ~23x. Its free cash flow yield is 3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
Pro-Dex, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.17 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Pro-Dex, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Irvine, US. The company is led by CEO Richard Lee Van Kirk Jr.. PDEX has traded publicly since 1986.
PDEX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence in the company's future performance.
- Community sentiment has shifted positively, with discussions highlighting Pro-Dex's innovative product pipeline.
- Market perception is buoyed by the company's recent strategic partnerships that enhance its competitive edge.
- Investors are optimistic about the potential growth in the medical device sector, where Pro-Dex operates.
Bear Case
- Concerns about supply chain disruptions could impact Pro-Dex's ability to meet demand effectively.
- Some community members express skepticism regarding the sustainability of recent revenue growth.
- Negative sentiment stems from broader market volatility, which may affect investor confidence in smaller firms like Pro-Dex.
- Recent earnings reports have raised questions about profit margins, leading to cautious views among analysts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PDEX Latest News
No recent news available for PDEX.
PDEX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PDEX.
Price Targets
Wall Street price target analysis for PDEX.
PDEX MoonshotScore
What does this score mean?
The MoonshotScore rates PDEX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard Lee Van Kirk Jr.
CEO
Richard Lee Van Kirk Jr. has extensive experience in the medical device industry, having held various leadership roles throughout his career. He has a strong background in engineering and management, which has been instrumental in guiding Pro-Dex's strategic direction. His educational credentials include a degree in engineering, equipping him with the technical knowledge necessary for overseeing product development and innovation.
Track Record: Under Richard's leadership, Pro-Dex has streamlined its operations and enhanced product offerings, resulting in improved profitability and market positioning. His focus on regulatory compliance and quality assurance has strengthened the company's reputation in the industry.
Pro-Dex, Inc. Healthcare Stock: Key Questions Answered
What does Pro-Dex, Inc. do?
Pro-Dex, Inc. specializes in designing and manufacturing powered surgical instruments for medical device OEMs. Their product offerings include battery-powered and electric surgical drivers and shavers, primarily used in orthopedic, thoracic, and craniomaxillofacial surgeries. Additionally, they provide engineering, quality, and regulatory consulting services, enhancing their value proposition in the healthcare sector.
What do analysts say about PDEX stock?
Analysts generally view Pro-Dex, Inc. as a solid player in the medical instruments sector, highlighting its strong profit margins and growth potential. Key valuation metrics indicate that the company is trading at a P/E ratio of 14.7, which is attractive compared to industry averages. Growth considerations include the increasing demand for powered surgical instruments and the potential for expansion into emerging markets.
What are the main risks for PDEX?
Pro-Dex, Inc. faces several risks that could impact its operations and market position. These include potential regulatory changes that may affect product approvals, intense competition from larger medical device manufacturers, and economic fluctuations that could reduce healthcare spending. Additionally, the company's dependence on a limited range of products may expose it to market volatility, necessitating a focus on diversification.
What are the key factors to evaluate for PDEX?
Pro-Dex, Inc. (PDEX) holds an AI score of 82/100 (high). P/E: 14.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does PDEX data refresh on this page?
PDEX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PDEX's recent stock price performance?
Pro-Dex, Inc. (PDEX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand with a strong reputation in the medical instruments sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PDEX overvalued or undervalued right now?
Pro-Dex, Inc. (PDEX) trades at 14.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PDEX?
Before investing in Pro-Dex, Inc. (PDEX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on current data and may be subject to change. Investors should conduct their own research before making decisions.